KaloBios Pharmaceuticals presented data from its Phase 1/2 study in persistent asthma for KB002, precursor chimeric anti-GM-CSF monoclonal antibody to KB003, at the American Academy of Allergy, Asthma & Immunology Annual Meeting in Austin, Texas. The findings demonstrated preliminary safety, tolerability, and signs of activity of anti- GM-CSF antibodies in asthma and support continued development of the company's Humaneered KB003 anti-GM-CSF monoclonal antibody in severe asthma. KB003 is currently in a Phase 2 trial in severe asthma patients inadequately controlled by corticosteroids. "These initial clinical results with KB002 in asthma are highly encouraging. KB002 was well-tolerated, with no significant adverse events in the study population. When KB002 was added to patients' standard of care treatment, the study also showed a reduction in airway inflammation and improvements in FEV1. Moreover, asthmatics with reversible FEV1 at baseline showed greater FEV1 responses than non-reversible patients. As a result, we are targeting this patient population in our ongoing Phase 2 KB003 study," said chief medical officer Nestor Molfino.
- Pharmaceuticals & Drug Trials